Minghao Tech Secures Tens of Millions in Series A Funding to Accelerate Commercialization of Vision Health Innovations

Minghao Technology, an innovative company specializing in medical vision technology, has officially announced the completion of its Series A financing round worth tens of millions of RMB. This round was led by the well-known investment firm Beijing Source Code Capital Co., Ltd., with participation from CITIC Medical Fund. The funding has injected new vitality into Minghao Technology’s development, further advancing the expansion of the company’s self-developed 5-degree precision fitting system and visual health solutions in both the medical and consumer markets. Additionally, it will accelerate the company's R&D innovation in ophthalmology and vision science.

Since its establishment, Minghao Technology has consistently adhered to innovation in ophthalmology and vision science. Guided by customer visual needs, based on clinical ophthalmology, and supported by the high-end precision manufacturing of optical lenses and advanced hard coating processes, the company has gradually achieved remarkable success in the field of medical optometry. Its core products cover multiple areas including medical refractive correction solutions, a 5-degree precision fitting system, high-quality optical lenses, and an SAAS system for optometry stores, holding a leading position in the industry and receiving high recognition from numerous experts. To date, the company's 5-degree precision fitting system and optical lens products have been introduced into nearly 300 medical institutions across China, covering 16 provinces and autonomous regions.

Mr. Zhu Xiao, founder, chairman and CEO of Minghao Technology, said: "We are honored to gain the trust and recognition of top institutions in the medical and health field in our Series A financing. This year, Minghao Technology’s fully independent innovative product for delaying the progression of myopia in Chinese children and adolescents — the 5-degree defocus lens 'Dian Dian Sunshine' — achieved gratifying results in clinical verification at Tongren Hospital. Its high myopia control rate of up to 70% has also gained affirmation from multiple parties and coverage by central media. Meanwhile, clinical research targeting different age groups, populations, and eye-use scenarios is being conducted in several well-known ophthalmic hospitals in China. In the future, we will continue to focus on developing vision health solutions for people with refractive errors worldwide. With the support of capital and the advantages of our technical platform, we will accelerate the R&D and productization of vision health technology, bringing better vision solutions to consumers more quickly, fulfilling our mission — 'Discovery, Making the World Clearer。

In addition, I would like to take this opportunity to welcome Professor Zhang Zuoming to officially join Minghao Technology and serve as the Dean of Minghao Vision Research Institute and Chief Scientist. Professor Zhang Zuoming is the former Director of the Clinical Medicine Teaching and Research Section of the Department of Aerospace Medicine at Air Force Medical University; he is also a review expert for projects such as the National Natural Science Foundation, the Ministry of Science and Technology's International Science and Technology Cooperation, and the Military Medical Achievement Award. He has long been dedicated to teaching, research, and clinical work in ophthalmology and vision science. We believe that with the addition of Professor Zhang, we will be able to better achieve the goals of Minghao Technology.To become the most trusted vision health company"The vision."

Mr. Kou Guan, Co-founder, Director and COO of Minghao Technology, stated: "We are grateful for the recognition from top-tier investment institutions of Minghao Technology's early achievements and future potential. This round of financing will provide strong support for the further market expansion of our existing precision fitting system and high-quality optical lens product line. It will also help us accelerate research and product development in the field of visual science to meet more unmet vision health needs."

At the same time, with the support of this round of investment institutions, we will officially enter the consumer market and launch two brand plans: "Wangshu Vision" and "Muyu Alliance." "Wangshu Vision" is positioned as a high-end vision management service, applying all of Minghao Technology's vision health research achievements in practice to help consumers achieve the goal of 'Wangshu.' "Muyu Alliance" focuses on innovative business models for the sale of cost-effective optical lenses, with the mission of 'allowing Chinese people to wear good lenses.' It aims to make domestically produced lens products, which are comparable to international high-end product lines, available at lower prices and with better services to benefit more people, creating a 'New National Brand Highlight.'

Dr. Zhang Yuhao, Executive Director of Beijing Source Code Capital Co., Ltd., stated: "Half of China's population is troubled by refractive errors, and the optometry industry is a major sector addressing people's needs for healthy vision. The industry’s preventive medicine attributes place it between serious clinical settings and consumer scenarios, which also poses challenges for establishing comprehensive product and industry standards. Minghao Technology is one of the few companies we have seen in the industry that focuses on consumer needs and validates efficacy through rigorous clinical standards. Its top-tier optical design and lens processing technology ensure the company can continuously develop high-quality, clinical-grade optometry products. We are pleased to participate in this round of financing for the company and look forward to their products benefiting a wide range of consumers soon."

CITIC Medical Fund stated: Eye health issues cover all age groups, combining both medical and consumer attributes, making it a large market and a major track. Minghao Technology, guided by clinical needs, independently develops innovative products with significant clinical effects, earning recognition from top domestic ophthalmology experts. It is also one of the few companies in China with the capability for independent lens design and high-end precision manufacturing.

Based on its own strengths and market demand, the company has created multiple brands and entered the visual consumption market, engaging in deep and innovative cooperation models with partners. We look forward to Minghao Technology, led by Mr. Zhu, benefiting more people with technology and becoming a trusted brand for visual health.